Galmed Pharmaceuticals Stock Today
| GLMD Stock | USD 2.26 0.03 1.31% |
PerformanceVery Weak
| Odds Of DistressLow
|
Galmed Pharmaceuticals is trading at 2.26 as of the 21st of March 2025, a 1.31 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.05. Galmed Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.66 M outstanding shares of which 4.08 K shares are currently shorted by private and institutional investors with about 0.26 trading days to cover. More on Galmed Pharmaceuticals
Moving together with Galmed Stock
Moving against Galmed Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Galmed Stock Highlights
Galmed Pharmaceuticals (GLMD) is traded on NASDAQ Exchange in USA. It is located in 16 Abba Hillel Road, Ramat Gan, Israel, 5250608 and employs 3 people. Galmed Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.79 M. Galmed Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.66 M outstanding shares of which 4.08 K shares are currently shorted by private and institutional investors with about 0.26 trading days to cover.
Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89.
Check Galmed Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRoughly 95.03 (percent) of Galmed Pharmaceuticals outstanding shares are held by general public with 1.89 % owned by insiders and only 3.08 pct. by outside corporations.
Check Galmed Ownership Details
Galmed Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Galmed Pharmaceuticals market risk premium is the additional return an investor will receive from holding Galmed Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | 0.343 | |||
| Treynor Ratio | (0.18) |
Galmed Stock Against Markets
Galmed Pharmaceuticals Corporate Management
| Shani Ganon | Human Manager | Profile | |
| Tali Gorfine | Medical Consultant | Profile | |
| Yael Hollander | Vice Strategy | Profile | |
| Guy Nehemya | COO Officer | Profile | |
| Niv Alon | Head PMO | Profile | |
| Doron Cohen | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.